After being fired, I became the light of medicine

Chapter 83 Yun Cong! (asking for monthly ticket)
There are many people like Zhou Zeping who have traveled thousands of miles back home.

When Qingshan Pharmaceutical announced that the Phase III clinical trial of "Acofenprofovir" would achieve a cure rate of 90%, hepatitis B patients from all over the country and all walks of life flocked to it!
It must also be said that because of the existence of the "Starlight Project", all hepatitis B projects go through the green approval channel, and "Avofovir" also enjoys fast approval treatment.

The Phase II clinical trial was passed in just twenty working days, and the Phase III clinical trial plan was approved simultaneously!

On November 11, "Afovir" will officially start the Phase III clinical trial.

But in fact,

Before the official opening on November 11, a large number of patients from all over the country flocked to Chengdu Third People's Hospital on November 10 to apply for the Phase III clinical trial of "Ekofovir".

On November 11, in just three days, all 3 trial places for "Ekofovir", which had been slow in its Phase II recruitment, were snapped up!
At this time, cytotoxicity and side effects seem unimportant compared to the 90% probability of curing hepatitis B!

Deputy Director Feng Gang was jaw-dropping. He had never seen any new drug recruit 600 subjects in just three days, and there was a steady stream of subjects coming!
But think about it, in China, there is no other virus that spreads as widely, has such a great impact, and is so harmful as hepatitis B!

Diabetes, high blood pressure, and even the epidemic virus are not allowed!
Feng Gang was amazed, but Director Chen Wen of the Infectious Disease Department was both in pain and happy.

Since participation in clinical trials requires a series of examinations and the establishment of medical records, the influx of a large number of patients has made the entire infectious disease department extremely busy.

Actually,
Compared with other departments, the Infection Department is a "clear-pocket clinic" and the overall revenue and profit of the department is not much. In addition, the Infection Department of a third-party hospital is not a star department, and the performance-based wages of the doctors and nurses in the department are negligible on weekdays.

Don't they want to make more money?
Yes I do!

But there are not many infected patients visiting the hospital. What can we do?
Now, a large number of hepatitis B patients have poured in. Not only are the outpatient doctors’ appointments fully booked every day, but even the inpatient department’s beds are almost full!

The entire department, from the director to the nurses, were all in pain and happy. They truly experienced the busyness and happiness of the hematology department back then!

of course.

The happiest person was Dean Zhou.

When he mobilized the doctors in the department to help advance the Phase II clinical trial of "Ekofovir", he actually wanted to repay Zhang Yang for his kindness.

But I didn’t expect that Qingshan Pharmaceutical is really doing well!

He watched with his own eyes as the cure rate of Ekofovir gradually increased from the initial 25% to 60%, and now to 90%!

Indirectly, it even led to the rapid development of the Infectious Diseases Department and the Hepatology Department of the Third People's Hospital!
With such enthusiasm, he couldn't help but feel excited inside!
You know, every year, every department in the country has an annual selection, and the Third People's Hospital of Chengdu currently has only one "Hematology Department" ranked in the top 20...

This time, because of "Ekofovir", so many hepatitis B patients have flocked to the hospital, and there will inevitably be a large number of hepatitis B patients admitted to the hospital for treatment in the future. If we can seize this opportunity, the ranking of the infectious disease department may not be able to be further improved!
His eyes became brighter and brighter. Last year, the Department of Hematology was personally praised by the leaders of the General Administration for its leading position in the clinical use of Avatrombopag Tablets and the cure of aplastic anemia.

If we can mention the ranking of infectious diseases again.
"Zhang Yang, you are truly my benefactor!"

……

Just when President Zhou wanted to make more progress, the news that Qingshan Pharmaceutical's "Ikefenprofovir" Phase II clinical data and the upcoming Phase III clinical trial also spread abroad.

Gilead Sciences, Inc., USA.

"Daniel, we must admit that we underestimated the research and development capabilities of this Chinese pharmaceutical company."

"I have carefully looked at their research and development progress. They started from 25% effective cure, then 45% and 60%. They have been moving forward very steadily and smoothly step by step."

"Moreover, most importantly, their research and development ideas are really novel, and the results are indeed unexpectedly good."

“Far exceeded my expectations!”

The speaker was John, the vice president of research and development at Gilead headquarters. He and President Daniel have been partners for more than ten years.

Daniel nodded, his eyes flashing with approval.

In fact, since they learned that "Ekofovir" has a 25% cure rate, they began to study "Ekofovir", which was "QS-001" at the time.

But I didn’t expect that Qingshan Pharmaceutical’s subsequent research and development speed would be so fast.

The reason is undoubtedly that Tsingshan Pharmaceutical has found the best way to solve the hepatitis B virus!
"Yes, John, I totally agree with you."

"The key reason why they were able to achieve significant results so quickly is that they found the right way!"

"To be honest, their R&D ideas and toxic substances have given me a lot of inspiration."

“So, they are well-deserving of the results they have achieved!”

The two were generous in their praise of Afovir because they both knew that when Gilead was developing a drug to cure hepatitis C, it had no idea at first, until it found the best solution, and in just six months, the cure rate increased from 20% to 95%.

It is exactly the same as the current "Afovir".

"Then what do we do next?"

Vice President John shrugged and said:

"At present, their 'Akofovir' has a high probability of achieving a 90% cure rate, and they will probably win the research funding for the 'Starlight Project' this time."

“What should we do with our Hepcludex project next? Should we stop it completely or give it up?”

Daniel did not answer directly, but frowned slightly as he fell into thought.

In fact, when major pharmaceutical companies around the world conduct research and development of multiple drugs, they will only invest a small amount of company resources and funds at the beginning. This is casting a wide net.

When one of the projects actually makes some breakthrough progress, the company will concentrate its resources and invest more research and development funds into it, with the aim of focusing funds on the most promising drugs.

Thanks to the "Starlight Project", Gilead has invested hundreds of millions of dollars in its hepatitis B drug Hepcludex. If it is stopped at this time, it means that almost all of the early investment will be wasted.

This is the cruelty of research and development in the pharmaceutical industry.

A few minutes later, Daniel shook his head slightly:

“It would be a shame to give up completely, after all, we have invested so much money and Hepcludex has made good progress.”

"Let the R&D team continue with their research and development. Of course, we can't just throw in a lot of resources like we did before, because Akofovir is already one step ahead of us."

Vice President John nodded, he completely agreed with Daniel's statement.

The pharmaceutical industry is not like other industries. It has a process of accumulation. Maybe this drug is not successful, but the accumulated experience and ideas will lead to success in another new drug.

"Should we continue to develop hepatitis B drugs, or learn from Tsingshan Pharmaceutical's research and development ideas for 'Ekofovir'?"

"why not?"

This time Daniel did not hesitate at all:
"Their approach to solving the hepatitis B virus problem is very novel, something we had not thought of or tried before."

"Although they are one step ahead of us now, even if they can really achieve a 90% cure rate, they can still continue to improve on drug toxicity and side effects."

"There are more than 3 million hepatitis B patients in the world. If we can make similar drugs, we may have sales!"

"HIV and hepatitis B have the same double-stranded structure of CCDNA. If we can use Qingshan Pharmaceutical's idea to cure hepatitis B, we may be able to use this idea to cure AIDS in the future."

"So, why shouldn't we learn from the best ideas in the world?"

John smiled.

This old partner's personality never changes no matter how much money he makes.

Daniel is always learning, and Gilead is always learning.

This is also the reason why Gilead is so powerful in the fields of liver disease and infectious diseases.

"Okay, Daniel, I will arrange for the R&D team to start studying Qingshan Pharmaceutical's 'Ekofovir' seriously."

"It won't be long before we fully understand the drug's mechanism."

……

PS: I have seen everyone’s latest comments, and they all say they are a bit watery.

Not just a little bit, it's a lot of water.

I accept it humbly. The reason is not that I am deliberately watering down, but that there may be a little deviation between my cognition and that of the readers! You are also welcome to comment and correct me, and I will work hard to correct it in the future.

I beg for a few monthly tickets with a sincere attitude. It would be too pitiful if I didn’t have a single monthly ticket today.

(End of this chapter)